For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

This is called, aptly, obstructive hypertrophic cardiomyopathy. This kind of obstruction is behind many of the more ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

A bounding pulse is when your heart beats strongly. You may feel your pulse in your neck, wrist, or foot. Here’s why it ...

Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic ...

It is used to replace the pumping action of the damaged heart ventricles while a person waits for a heart transplant. Other ...

Shares of biopharma outfit Edgewise Therapeutics ( EWTX -4.14%) soared more than 50% today, reaching a three-year high ...

Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD, discuss the use of beta-blocker therapy following acute MI ...

Type 2 diabetes impacted left ventricular and atrial function in patients with hypertrophic cardiomyopathy, emphasizing the need for diabetes surveillance.

ARVC is a genetic condition of the heart muscle that can cause arrhythmias (abnormal heartbeats), heart failure, and sudden ...

Background Pregnant patients with single ventricle (SV) physiology carry a high risk of spontaneous pregnancy loss (SPL), yet the clinical factors contributing to this risk are not well defined.

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price ...